Katie Kosko

AZUHT-PRODUCTIONwarmup

Women are underrepresented in kidney cancer clinical trials, especially in the advanced and metastatic settings, according to study findings presented during the 25th Annual Meeting of the Society of Urologic Oncology.
Madison Krischak, MD, of the University of Michigan, Ann Arbor, and colleagues evaluated the number of women enrolled in urologic oncology clinical trials compared with the American Cancer Society’s (ACS) estimated incidence of these types of cancers among women.
Clinical trial enrollment demographics were found using the Aggregate Analysis of ClinicalTrials.gov database for bladder and kidney cancer trials registered since January 1, 2007. The researchers coded trials by cancer type, and descriptive statistics were calculated for proportion of women enrolled for trials of each cancer type.
Nearly 600 clinical trials involving kidney cancer (n=414) and bladder cancer (n=176) were included in the study.
The researchers observed that the proportion of women enrolled in kidney cancer clinical trials is below what is expected based on annual incident proportions. Enrollment falls short by approximately one in 14 women with kidney cancer, the researchers said. The median proportion of women in kidney cancer trials was 29%, with a mean of 31%, compared with the ACS’s estimated proportional incidence of kidney cancer in women, which is 36%.
“Ensuring representative enrollment is crucial for the generalizability of trial outcomes and addressing potential gender disparities in treatment efficacy and safety,” the researchers said.
In bladder cancer trials, the expected proportion of women with bladder cancer were enrolled. The median proportion of women was 22%, with a mean of 25%. These percentages are similar to the ACS’s estimated proportional incidence of bladder cancer in women (24%).
“Further work is needed to ensure adequate representation of women in kidney cancer trials,” the researcher said. “While women are not currently underserved in bladder cancer trials, efforts should continue to maintain representative enrollment of women to ensure equitable and effective urologic cancer treatment across sexes and genders.”
Reference
Krischak M, Semerjian A, Piatt G, et al. Are women underrepresented in urologic oncology clinical trials? Poster #21. Presented at the 25th Annual Meeting of the Society of Urologic Oncology; December 4-6, 2024; Dallas, Texas.

Kidney Cancer Clinical Trials Lack Women Representation

SUO 2024

Tamara Thomas

Dr. Von Nguyen Discusses AI Use in Medicine and Population Health

AI in Medicine

Women with High Androgen PCOS Face Increased Risk of Heart, Liver Disease

Diabetes in Women

Latest News

Enrollment falls short by approximately one in 14 women with kidney cancer.

About Us

Editorial Policy

Contributors & Partners

eNewsletters

Contact Us

Work With Us

Advertising

GU Oncology Now

Blood Cancers Today

Cancer Nursing Today

DocWire News

MashupMD

Food Allergy Roundtable Discussions

Autoimmune Disease

Allergy

Blood Cancers

— Multiple Myeloma

Breast Cancer

Colorectal Cancer

Lung Cancer

Pancreatic Cancer

Prostate Cancer

Cancer

Diabetes

Heart Failure

Heart Disease Prevention

Heart Health

HIV Roundtable Discussions

COVID-19

Infectious Diseases

Asthma

COPD

Pulmonology

Digital Health

Workforce News

Public Health

Dermatology

Gastroenterology

Kidney Disease

Neurology

Obesity

Pediatrics

Sickle Cell Disease

Eye Disease

Video Insights

More

Gynecologic Cancer

Heart Disease in Women

Menopause

Reproductive Health

Women’s Neurology

Well Woman Today

Roundtables

Podcasts

Conferences

Viewpoints

Career Center

Subscribe